tbuckley/cabot-search huggingface dataset:
Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers
Authors: Tatsuo Hata, Marco Dal Molin, Seung-Mo Hong, Koji Tamura, Masaya Suenaga, Jun Yu, Hiraku Sedogawa, Matthew J. Weiss, Christopher L. Wolfgang, Anne Marie Lennon, Ralph H. Hruban, Michael G. Goggins
Journal: Clinical Cancer Research (2017)

Purpose: Pancreatic cysts are common and pose diagnostic and management challenges. Pancreatic cyst fluid markers have the potential to aid in the management of cysts with concerning imaging findings. Our aim was to evaluate cyst fluid methylated DNA markers for their accuracy for predicting the histologic grade of neoplastic pancreatic cysts.Experimental Design: Pancreatic cyst fluid samples from 183 patients (29 discovery and 154 validation) aspirated after surgical resection were analyzed for methylated DNA at selected genes (SOX17, BNIP3, FOXE1, PTCHD2, SLIT2, EYA4, and SFRP1) using methylation-specific droplet-digital PCR (dd-QMSP). Methylated DNA levels were evaluated for their accuracy at predicting the grade of dysplasia of the pancreatic cyst.Results: All six markers evaluated in the validation set could accurately distinguish high-risk cystic neoplasms (with high-grade dysplasia and/or associated invasive cancer) from low-risk cysts (lower grades of dysplasia) with accuracies from 79.8% to 83.6%. Methylated SOX17 had the highest overall accuracy as a single marker (sensitivity, 78.4%; specificity, 85.6%; accuracy 83.6%, cutoff; 25 methylated DNA molecules/μL cyst fluid). The best four-gene combination had 84.3% sensitivity, 89.4% specificity, and 88.0% accuracy at distinguishing cysts with high-grade dysplasia and/or invasive cancer from those without. All six markers were independent predictors of having invasive cancer/high-grade dysplasia after adjusting for clinical/imaging factors known to be associated with grade of dysplasia. The combination of methylated SOX17 with cytology better predicted neoplastic grade than cytology alone.Conclusions: A panel of methylated gene markers quantified by dd-QMSP can be used to predict the grade of dysplasia of pancreatic cysts. Clin Cancer Res; 23(14); 3935-44. ©2017 AACR.
CD44-Ligation Triggers IL-1, GM-CSF and IL-8 Driven Differentiation Pathways in Human Monoblastic Leukemia Cells.
Authors: Florence Smadja-Joffe, Jacques Delaunay, Junyuan Qi, Zeineb Gadhoum, Laetitia Durand Ingeneer, Christine Chomienne
Journal: Blood (2006)
Role of MRD Monitoring in Childhood Acute Lymphoblastic Leukemia after Allogeneic Transplantation.
Authors: Adriana Balduzzi, Sonia Bonanomi, Monica Manenti Tech, Maria Dassi, Giovanni Cazzaniga, Maria Rosa Riva, Simona Songia Tech, Paolo Perseghin, Luca Mascaretti, Cornelio Uderzo, Andrea Biondi
Journal: Blood (2004)
Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia
Authors: Yan Li, Qingyu Xu, Na Lv, Lili Wang, Hongmei Zhao, Xiuli Wang, Jing Guo, Chongjian Chen, Yonghui Li, Li Yu
Journal: Journal of Hematology & Oncology (2017)

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. AML is a heterogeneous malignancy characterized by distinct genetic and epigenetic abnormalities. Recent genome-wide DNA methylation studies have highlighted an important role of dysregulated methylation signature in AML from biological and clinical standpoint. In this review, we will outline the recent advances in the methylome study of AML and overview the impacts of DNA methylation on AML diagnosis, treatment, and prognosis.
Emotional memory: From affective relevance to arousal
Authors: Alison Montagrin, David Sander
Journal: Behavioral and Brain Sciences (2016)

Arousal is typically conceived as a key component of emotional response. We describe here the psychological processes thought to elicit arousal - in particular, the processes involved in the appraisal of affective relevance. The key role of relevance in attentional and memory processing, and its links with arousal, is discussed with respect to the GANE (glutamate amplifies noradrenergic effects) model described by Mather et al.
IMPS-01Gr-1<sup>+</sup>/CD11b<sup>+</sup>MYELOID CELLS ARE REQUIRED FOR NATURAL KILLER CELL-MEDIATED ERADICATION OF GALECTIN-1-DEFICIENT GLIOMA
Authors: Gregory Baker, Peter Chockley, Daniel Zamler, Maria Castro, Pedro Lowenstein
Journal: Neuro-Oncology (2015)

Glioblastoma (GBM) is highly infiltrated by immune cells of the myeloid lineage; however, the immunosuppressive microenvironment established by GBM favors anti-inflammatory activity in these cells and in turn promotes tumor immune escape. We have recently shown that shRNA-mediated knockdown of the β-galactoside-binding lectin galectin-1 (gal-1) in malignant glioma cells leads to glioma eradication within a week of intracranial engraftment (Baker et al, Cancer Research. 2014; 74:5079-90). NK cells are central to the rejection of gal-1-deficient glioma as immunodepletion of these cells with anti-asialo GM1 or NK1.1 antibodies permitted the growth of these tumors. We now report that immunodepletion of Gr-1+ myeloid cells in RAG1−/- mice also permits the growth of gal-1-deficient glioma, despite the presence of NK cells. This intriguing observation establishes that NK cells require collateral support by Gr-1+ myeloid cells to exert anti-glioma immune surveillance activity. We found that gal-1-deficient mouse GL26-Cit cells are pro-inflammatory as they upregulate expression of chemokines CXCL10/IP-10 and RANTES. Seven-fold more Gr-1+/CD11b+ myeloid cells infiltrated the gal-1-deficient GL26-Cit microenvironment compared to infiltration into control GL26-Cit tumors. Myeloid infiltration was followed by a 10-fold increase in the number of NK cells. Implantation of gal-1-deficient GL26-Cit cells into the brain of B6.Myd88−/- mice failed to recruit peripheral blood mononuclear cells (PBMCs) into the tumor microenvironment 72 hours post-engraftment, thus permitting gal-1-deficient glioma growth. This implied that TLR/Myd88−/- signaling is required to induce the entry of PBMCs into the gal-1-deficient microenvironment to cause tumor eradication. Experiments are now underway to determine the identity of the biomolecular factors produced by gal-1-deficient GL26-Cit glioma cells responsible for initiating Myd88 signaling and the receptors and cells in which Myd88 signaling is necessary for glioma rejection. These studies identify a novel innate immune network necessary and sufficient for early glioma rejection without requiring contributions from the adaptive immune system.
Vitamin K and osteoporosis: Myth or reality?
Authors: Andrea Palermo, Dario Tuccinardi, Luca D'Onofrio, Mikiko Watanabe, Daria Maggi, Anna Rita Maurizi, Valentina Greto, Raffaella Buzzetti, Nicola Napoli, Paolo Pozzilli, Silvia Manfrini
Journal: Metabolism (2017)
Second Unrelated Donor (URD) Transplant as a Rescue Strategy for 122 Patients with Primary Non Engraftment: Results from the CIBMTR
Authors: Jeffrey R. Schriber, Manza- A Agovi, Karen K Ballen, Andrea Bacigalupo, Gregory A. Hale, Vikas Gupta, Hillard M. Lazarus, Mark R. Litzow, David I. Marks, Roger H. Giller, Richard T. Maziarz, Martin Bornhauser, Luis M. Isola, Christopher Bredeson, J. Douglas Rizzo
Journal: Blood (2008)
Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19–28z CAR-Targeted T Cells
Authors: Marco L Davila, Isabelle Riviere, Xiuyan Wang, Jae H. Park, Jolanta Stefanski, Clare Taylor, Qing He, Malgorzata Olszewska, Teresa Wasielewska, Oriana Borquez-Ojeda, Jinrong Qu, Shirley Bartido, Joseph G. Jurcic, Dan Douer, Mark G. Frattini, Michel Sadelain, Renier J Brentjens
Journal: Blood (2012)
Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD).
Authors: Jason R. Westin, Rima M. Saliba, Marcos de Lima, Amin Alousi, Chitra Hosing, Muzaffar H. Qazilbash, Issa F. Khouri, Elizabeth J. Shpall, Richard Champlin, Daniel R. Couriel
Journal: Blood (2007)
Multiple HCV Amino Acid Variants Associate with Interferon Lambda Polymorphism in Genotype 1a, 1b and 3a Infections
Authors: Nimisha Chaturvedi, Ramakrishna K. Chodavarapu, Evguenia S. Svarovskaia, Hongmei Mo, Anu O. Osinusi, Ming Lin, Diana M. Brainard, Mani Subramanian, John G. Mchutchison, Stefan Zeuzem, Jacques Fellay
Journal: Hepatology (2016)

Reference EPFL-CONF-225193Afficher la publication dans Web of Science Notice creee le 2017-01-24, modifiee le 2017-01-26
The significance of serum interleukin-10 on the outcome of unresectable hepatocellular carcinoma (HCC).
Authors: S. L. Chan, F. Mo, S. C. Wong, E. P. Hui, H. H. Loong, T. Mok, A. T. Chan, W. Yeo
Journal: Journal of Clinical Oncology (2011)

205 Background: Serum interleukin-10 (IL-10) is associated with active hepatitis in patients (pts) with hepatitis B viral (HBV) infection. In HBV-related HCC, elevation of serum IL-10 is frequently observed but its significance on the outcome of HCC is unclear. Methods: A prospective cohort of newly diagnosed and inoperable HCC was recruited from a multidisciplinary clinic from Prince of Wales Hospital from 2006 to 2008. The baseline demographics, tumor characteristics/stage, laboratory parameters, virologic factors (HBV DNA, antiviral therapy) and first-line treatment modality were documented at the time of diagnosis. Serum IL-10 was measured by enzyme-linked immunosorbent essay. Univariate and multivariate analyses were conducted. Overall survival (OS) was the primary endpoint. Results: Total 180 new cases of inoperable HCC were evaluated. The median follow-up time was 15.5 months. Median age was 60.5 years. Most (159 pts; 88.3%) were males. 81.1% of them were positive for HBsAg. Total 120 (66.7%) had radiologic evidence of cirrhosis. 20 (11.1%), 85 (47.2%) and 75 (41.7%) received locoablative, trans- arterial/systemic therapy and supportive care respectively. The mean level of serum IL-10 was 18.1pg/ml (range: 2.8-11.7). 114 (63.3%) had log IL-10 higher than 1.0 pg/ml. Pts with log IL-10 &gt;1.0 pg/ml had significantly worse OS than those with log IL-10≤ 1.0 pg/ml (14.8 vs. 4.5 months; HR 2.39; p&lt;.0001). Multivariate analysis found log IL-10 (HR=2.57; p=0.005), CLIP score, TNM stage, treatment modality and the use of anti-viral therapy for HBV infection be the independent prognostic factors. Exploratory analyses showed that pts with Log IL-10&gt;1.0pg/ml had higher ALT and HBV DNA, lower albumin, higher chance of ascites, worse Child-Pugh stage and worse tumor stage (Table). Conclusions: Serum IL-10 is an independent prognostic factor for inoperable HCC. Pts with high IL-10 level have poorer liver reserves and worse tumor staging. [Table: see text] No significant financial relationships to disclose.
Anti-CD20 and Anti-CD52 Monoclonal Antibodies Enhance Cytotoxicity of Bortezomib Against Chronic Lymphocytic Leukemia Cells.
Authors: Piotr Smolewski, Markus Duechler, Anna Linke, Barbara Cebula, Olga Grzybowska-Izydorczyk, Medhat Shehata, Tadeusz Robak
Journal: Blood (2005)
Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies.
Authors: Wyndham H Wilson, O. O’Connor, Myron S. Czuczman, Ann LaCasce, J. Gerecitano, John P. Leonard, Anil Tulpule, Hao Xiong, Yi-Lin Chiu, Todd Busman, Raymond A. Knight, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse
Journal: Blood (2008)
Cell Cycle Progression and Self-Renewal Divisions of Cord Blood Derived CD34+ Cells Treated with the Polyamine Copper-Chelator Tetraethylenepentamine.
Authors: Toni Peled, Noga R. Goudsmid, Frida Grynspan, Sophie Adi, Efrat Landau, Arnon Nagler, Eitan Fibach, Yaron Daniely
Journal: Blood (2004)
Multimodal Neuroimaging of Frontolimbic Structure and Function Associated With Suicide Attempts in Adolescents and Young Adults With Bipolar Disorder
Authors: Jennifer A.Y. Johnston, Fei Wang, Jie Liu, Benjamin N. Blond, Amanda Wallace, Jiacheng Liu, Linda Spencer, Elizabeth T. Cox Lippard, Kirstin L. Purves, Angeli Landeros-Weisenberger, Eric Hermes, Brian Pittman, Sheng Zhang, Robert King, Andrés Martin, Maria A. Oquendo, Hilary P. Blumberg
Journal: American Journal of Psychiatry (2017)

Objective: Bipolar disorder is associated with high risk for suicidal behavior that often develops in adolescence and young adulthood. Elucidation of involved neural systems is critical for prevention. This study of adolescents and young adults with bipolar disorder with and without a history of suicide attempts combines structural, diffusion tensor, and functional MR imaging methods to investigate implicated abnormalities in the morphology and structural and functional connectivity within frontolimbic systems. Method: The study had 26 participants with bipolar disorder who had a prior suicide attempt (the attempter group) and 42 participants with bipolar disorder without a suicide attempt (the nonattempter group). Regional gray matter volume, white matter integrity, and functional connectivity during processing of emotional stimuli were compared between groups, and differences were explored for relationships between imaging modalities and associations with suicide-related symptoms and behaviors. Results: Compared with the nonattempter group, the attempter group showed significant reductions in gray matter volume in the orbitofrontal cortex, hippocampus, and cerebellum; white matter integrity in the uncinate fasciculus, ventral frontal, and right cerebellum regions; and amygdala functional connectivity to the left ventral and right rostral prefrontal cortex. In exploratory analyses, among attempters, there was a significant negative correlation between right rostral prefrontal connectivity and suicidal ideation and between left ventral prefrontal connectivity and attempt lethality. Conclusions: Adolescent and young adult suicide attempters with bipolar disorder demonstrate less gray matter volume and decreased structural and functional connectivity in a ventral frontolimbic neural system subserving emotion regulation. Among attempters, reductions in amygdala–prefrontal functional connectivity may be associated with severity of suicidal ideation and attempt lethality.
Dnmt3a Is Essential for Hematopoietic Stem Cell Differentiation
Authors: Grant A. Challen, Deqiang Sun, Mira Jeong, Min Luo, Jaroslav Jelinek, Aparna Vasanthakumar, Alexander Meissner, Jean-Pierre Issa, Lucy Godley, Wei Li, Margaret A. Goodell
Journal: Blood (2011)
Richmond T. Prehn: In Memoriam (1922–2016)
Authors: Lawrence A. Loeb
Journal: Cancer Research (2017)

![][1] 

On November 7, 2016, the cancer research community lost Dr. Richmond Prehn (Rich), a lifelong supporter of AACR and former member of its board, a penetrating theoretician, and a decisive experimentalist. Most scientists think in incremental steps and fear taking great leaps
The Small Molecule Pan-Bcl-2 Inhibitor GX15-070 Induces Apoptosis In Vitro in Mantle Cell Lymphoma (MCL) Cells and Exhibits a Synergistic Effect in Combination with the Proteasome Inhibitor Bortezomib.
Authors: Patricia Perez Galan, Gael Roue, Neus Villamor, Elias Campo, Dolors Colomer
Journal: Blood (2005)
Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL
Authors: Franck Rapaport, Jay Patel, Jie He, Timothy A Brennan, Michelle Nahas, Sohail Balassubramanian, Geoff Otto, Doron Lipson, Phil Stephens, Vincent A. Miller, Janis Racevskis, Mark R Litzow, Peter H. Wiernik, Anthony H. Goldstone, Selina Luger, Marcel van den Brink, Agnes Viale, Jacob M. Rowe, Martin S. Tallman, Ari Melnick, Elisabeth Paietta, Mithat Gonen, Ross L. Levine
Journal: Blood (2015)
Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen
Authors: Felicity J Burt, Weiqiang Chen, Jonathan J Miner, Deborah J Lenschow, Andres Merits, Esther Schnettler, Alain Kohl, Penny A Rudd, Adam Taylor, Lara J Herrero, Ali Zaid, Lisa F P Ng, Suresh Mahalingam
Journal: The Lancet Infectious Diseases (2017)
The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload.
Authors: E. R. Dennis, J. J. Fox, S. M. Larson, J. S. Farrelly, L. H. Schwartz, H. Schöder, E. C. Haupt, L. S. Borwick, H. I. Scher, M. J. Morris
Journal: Journal of Clinical Oncology (2011)

4635 Background: Prostate Cancer Working Group 2 (PCWG2) Concensus Criteria proposed time-to-event endpoints in early-phase clinical trials. Chief among these was time to radiographic progression for bone scintigraphy, based on a standardized definition with additional specifications to distinguish early “flare” from true progression. The Prostate Cancer Clinical Consortium (PCCTC) created a bone scan data capture tool to standardize and operationalize these definitions in clinical trials. We tested the hypothesis that the tool would improve clinical trial workload and data accuracy. Methods: At Memorial Sloan-Kettering Cancer Center (MSKCC), the PCCTC bone scan tool was vetted through 9 versions over the course of 3 years. Reproducibility, ease-of-use and accuracy were tested over the course of 12 clinical trials. To assess workload, accruals at MSKCC of two phase III trials using the same drug, contracting research organization (CRO) and electronic data capture system were analyzed. The first trial did not use the PCCTC tool and the second incorporated it in its data collection plan and case report form. Workload and data capture adequacy for each trial were determined by examining the number of imaging queries from the CRO as a function of the number of scans and patients. Results: Data from this analysis are found in the table below. The relative number of queries per scan was reduced by 86.71% by use of the tool. The queries:scan ratios were 0.82 versus 0.11 before and after the use of the tool respectively; likewise, the ratios of queries:patient were 2.81 vs. 0.56. Conclusions: Using the PCCTC bone scan data capture tool, data are more completely reported and workload is decreased. The reproducibility and feasibility of the tool is further being tested in phase III studies in which PCWG2 criteria are being clinically qualified. These efforts to quantitate, standardize and qualify imaging data advance the goal of developing an imaging biomarker in metastatic prostate cancer. Support: DOD PC071610. 2008 phase III 2009 phase III without tool with tool Patients 16 41 Queries 45 23 Scans 55 211 Avg queries/patient 2.81 0.56 Avg scans/patient 3.44 5.15 Queries/scan 0.82 0.11 Reduction in queries/scan with tool -86.71%
Rituximab/Chemotherapy Induction Treatment Followed by High-Dose Therapy and Autologous Transplantation in Patients with Mantle Cell Lymphoma.
Authors: C. Thieblemont, D. Antal, L. Lacotte-Thierry, V. Delwail, F. Bouafia, S. Tartas, A.S. Michallet, D. Espinouse, C. Giraud, G. Salles, F. Guilhot, B. Coiffier
Journal: Blood (2004)
Which Hemochromatosis Mouse Model Is Best for You?: Accessing Information about Mouse Mutant Phenotypes and Their Human Disease Associations.
Authors: Hiroaki Onda, Cynthia L. Smith, Donna L. Burkart, Linda L. Washburn, Ira Lu, Susan M. Bello, Monika Tomczuk, Anna Anagnostopoulus, Megan Cassell, Janan T. Eppig
Journal: Blood (2005)
c-Myc downregulation is required for preacinar to acinar maturation and pancreatic homeostasis
Authors: Victor J Sánchez-Arévalo Lobo, Luis César Fernández, Enrique Carrillo-de-Santa-Pau, Laia Richart, Isidoro Cobo, Jaroslaw Cendrowski, Ulisses Moreno, Natalia del Pozo, Diego Megías, Bernardette Bréant, Christopher V Wright, Mark Magnuson, Francisco X Real
Journal: Gut (2017)

<h3>Background and aims</h3> c-Myc is highly expressed in pancreatic multipotent progenitor cells (MPC) and in pancreatic cancer. The transition from MPC to unipotent acinar progenitors is associated with c-Myc downregulation; a role for c-Myc in this process, and its possible relationship to a role in cancer, has not been established. <h3>Design</h3> Using coimmunoprecipitation assays, we demonstrate that c-Myc and Ptf1a interact. Using reverse transcriptase qPCR, western blot and immunofluorescence, we show the erosion of the acinar programme. To analyse the genomic distribution of c-Myc and Ptf1a and the global transcriptomic profile, we used ChIP-seq and RNA-seq, respectively; validation was performed with ChIP-qPCR and RT-qPCR. Lineage-tracing experiments were used to follow the effect of c-Myc overexpression in preacinar cells on acinar differentiation. <h3>Results</h3> c-Myc binds and represses the transcriptional activity of Ptf1a<i>.</i> c-Myc overexpression in preacinar cells leads to a massive erosion of differentiation. In adult <i>Ela1-Myc</i> mice: (1) c-Myc binds to Ptf1a, and Tcf3 is downregulated; (2) Ptf1a and c-Myc display partially overlapping chromatin occupancy but do not bind the same E-boxes; (3) at the proximal promoter of genes coding for digestive enzymes, we find reduced PTF1 binding and increased levels of repressive chromatin marks and PRC2 complex components. Lineage tracing of committed acinar precursors reveals that c-Myc overexpression does not restore multipotency but allows the persistence of a preacinar-like cell population. In addition, mutant KRas can lead to c-Myc overexpression and acinar dysregulation. <h3>Conclusions</h3> c-Myc repression during development is crucial for the maturation of preacinar cells, and c-Myc overexpression can contribute to pancreatic carcinogenesis through the induction of a dedifferentiated state.
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia
Authors: Boglarka Gyurkocza, Rainer F. Storb, Barry Storer, Thomas Chauncey, Dietger Niederwieser, Judith Shizuru, Amelia Langston, Michael Pulsipher, Christopher Bredeson, Richard T. Maziarz, Benedetto Bruno, Finn Petersen, Michael Maris, Edward Agura, Andrew M. Yeager, Wolfgang A. Bethge, Firoozeh Sahebi, Lars Vindelov, Peter A. McSweeney, Frederick R. Appelbaum, David G. Maloney, Brenda M. Sandmaier
Journal: Blood (2008)
The Src Kinases Play a Crucial Role in the Growth of Hematopoietic Cells Transformed with Constitutively Activated Stat5 Mutants.
Authors: Remy Nyga, Fabrice Gouilleux, Flora Cartier, Christian Pecquet, Aline Regnier, Jean-Pierre Marolleau, Jacques Rochette, Richard Moriggl, Hicham Bouhlal, Kaiss Lassoued
Journal: Blood (2009)
Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database
Authors: Anita Kumar, Ann Vanderplas, Ann S. LaCasce, Maria A. Rodriguez, Allison L. Crosby, Eva Lepisto, Myron S. Czuczman, Auayporn Nademanee, Joyce Niland, Leo I. Gordon, Michael Millenson, Andrew D. Zelenetz, Jonathan W. Friedberg, Gregory A. Abel
Journal: Blood (2010)
A Phase I/II Trial of Lenalidomide and RCHOP (R2CHOP) in Patients with Newly Diagnosed Diffuse Large B -Cell (DLBCL) and Follicular Grade 3 Lymphoma.
Authors: Grzegorz S. Nowakowski, Betsy LaPlant, Thomas Habermann, David J Inwards, Patrick L Johnston, Clive S. Zent, Craig B. Reeder, Thomas E Witzig
Journal: Blood (2009)
Neo-Vasculogenesis In Vivo Is Facilitated by Oxygen Sensing Mesenchymal Stem and Pogenitor Cells
Authors: Nicole A Hofmann, Anna Ortner, Rodrigo O Jacamo, Andreas Reinisch, Katharina Schallmoser, Margareta Fruewirth, Clemens Diwoky, Rokhsareh Rohban, Christine Beham-Schmid, Michael Andreeff, Dirk Strunk
Journal: Blood (2011)
Erratum: Acute myeloid leukemia targets for bispecific antibodies
Authors: S S Hoseini, N K Cheung
Journal: Blood Cancer Journal (2017)

Correction to: Blood Cancer Journal (2017) 7, e522; doi:10.1038/bcj.2017.2; published online 3 February 2017 Following the online publication of this article, the authors noted that the following funding information needed to be included: This work was supported through the NIH/NCI Cancer Center Support Grant P30 CA008748.
Treatment of Primary CNS Lymphoma with Induction High-Dose Methotrexate, Temozolomide, Rituximab Followed by Consolidation Cytarabine/Etoposide: A Pilot Study with Biomarker Analysis.
Authors: Samar Issa, Arthur Shen, Jon Karch, Cigall Kadoch, Marc Shuman, Lloyd Damon, James Rubenstein
Journal: Blood (2007)